Vaccine

Engineered dengue virus mRNA in lipid nanoparticles triggers helpful antibodies that safely block virus entry into liver cells

Updated

Abstract

Immunization with chimeric NS1 antigen resulted in a predominant IgG2a response and reduced viral load in Balb/C mice.

  • A truncated NS1 antigen and a chimeric NS1 antigen were designed to avoid antibody-dependent enhancement.
  • Both antigens were successfully expressed in Huh7 cells, with the full-length and chimeric NS1 being secreted.
  • Mice immunized with chimeric NS1 did not show cross-reactivity with endothelial cells.
  • Chimeric NS1 was effective in neutralizing the entry of NS1 into liver cells.
  • These findings indicate that chimeric NS1 may be a safer option for dengue vaccine development.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free